The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 15, 2022

Filed:

Dec. 12, 2016
Applicant:

Ruprecht-karls-universität Heidelberg, Heidelberg, DE;

Inventors:

Georg Gdynia, Heidelberg, DE;

Wilfried Roth, Schwetzingen, DE;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 38/10 (2006.01); A61P 37/02 (2006.01); A61K 38/00 (2006.01); C07K 14/52 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C07K 14/52 (2013.01); A61K 35/17 (2013.01); A61K 38/10 (2013.01); A61K 38/1709 (2013.01); A61K 38/19 (2013.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); C12N 15/11 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention relates to a combined preparation comprising (i) a modulator of pyruvate kinase M2 (PKM2) activity, and (ii) an agent providing high mobility group box 1 (HMGB1) polypeptide or a derivative thereof. The present invention also relates to the aforesaid combined preparation for use as a medicament and for use in the treatment of inappropriate cellular proliferation, preferably in the treatment of cancer. Moreover, the present invention relates to a method for determining whether a subject suffering from inappropriate cellular proliferation is amenable to a treatment comprising administration of a modulator of PKM2 activity as the only PKM2 inhibitor and to treatment methods related thereto.


Find Patent Forward Citations

Loading…